Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial

NCT07190027 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

246

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Arm 1： Standard Synchronous Group
DRUG: Arm 2：Fixed Delay Group
DRUG: Arm 3： Individualized Delay Group

Sponsor

First Affiliated Hospital of Wenzhou Medical University